

ASX RELEASE

30th January 2020

Amplia Provides Quarterly Cash Update

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) is today releasing ASX Appendix 4C – Statement of Cashflows. The statement describes the Company’s cash expenditure during the period of October to December 2019 and provides a cash position effective 31st December 2019. Accordingly, the statement does not include details of the \$0.93 million raised in the share placement announced on 20 January (refer ASX Announcement “Amplia Therapeutics Undertake Placement) and completed on 24 January 2020.

During the last Quarter the Company completed the following clinic-enabling milestones:

- Dosing in the first pivotal toxicology study of AMP945 was completed. The study was designed to assess three different dose levels of AMP945 in rodents and was performed according to the principles of Good Laboratory Practice (GLP). The results of this study are expected in March 2020.
- Prior to the first pivotal toxicology study, several foundational studies, required to support the definitive toxicology, were completed. These included development and validation of biological assays to detect AMP945 in plasma, assessment of the metabolism of AMP945 and confirmation that formulations of AMP945 were suitable for use in toxicology studies.
- The company has been monitoring the stability of the GMP batch of AMP945 manufactured in 2019. In December we received stability data showing that AMP945 remained within specification and is on track for use in Amplia’s planned clinical studies.
- In early January, the Company made a submission to the US Food and Drug Administration (FDA) requesting that AMP945 be granted orphan drug designation in pancreatic cancer. If approved, the FDA’s orphan drug designation will facilitate the development of AMP945 in the USA by allowing Amplia to request waivers of certain regulatory fees. Subject to approval, orphan drug designation would also provide eligibility for 7 years of marketing exclusivity.

In the next Quarter, the Company plans to report on the following objectives:

- The pivotal clinic-enabling toxicology studies will be completed keeping the Company on track to initiate clinical trials of its lead FAK inhibitor, AMP945, during 2020.
- Based on responses to its requests for proposals, a vendor will be selected to support Amplia’s inaugural clinical study of AMP945.
- The Company continues to expand its network of collaborations with leading research institutes. We expect to announce new collaborations which will underpin the planned Phase 2 clinical studies of AMP945 and AMP886.
- The Company plans to file a new international Patent Cooperation Treaty (PCT) application. This application follows on from the provisional application filed in March 2019 protecting the preferred salt form of AMP945. In jurisdictions where it is granted, the patent will provide protection for the preferred form of AMP945 out to 2039.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

Level 29, 55 Collins Street, Melbourne VIC 3000

Email info@ampliatx.com

www.ampliatx.com

For Further Information

Dr. John Lambert
Chief Executive Officer
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Amplia Therapeutics Limited

ABN

16 165 160 841

Quarter ended ("current quarter")

31 December 2019

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers		
1.2 Payments for		
(a) research and development	<153>	<741>
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs	<105>	<416>
(f) administration and corporate costs	<51>	<184>
1.3 Dividends received (see note 3)		
1.4 Interest received	-	3
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
Intellectual property costs	<4>	<53>
D&O insurance	<49>	<49>
Miscellaneous	-	-
1.9 Net cash from / (used in) operating activities	<362>	<1,440>

2.	Cash flows from investing activities		
2.1	Payments to acquire:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment	-	-
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	1,219
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities	<10>	<180>
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	Net cash from / (used in) financing activities	<10>	1,039

Quarterly cash flow report for entities subject to Listing Rule 4.7B

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	1,207	1,241
4.2	Net cash from / (used in) operating activities (item 1.9 above)	<362>	<1,440>
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	<10>	1,039
4.5	Effect of movement in exchange rates on cash held	2	<3>
4.6	Cash and cash equivalents at end of period	837	837

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	34	560
5.2	Call deposits	803	647
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	837	1,207

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1.2	15
6.2	Aggregate amount of payments to related parties and their associates included in item 2.3	-

Item 6.1 includes payments of \$15,000 to an entity associated with the Director/Secretary for the provision of company secretarial services.

Quarterly cash flow report for entities subject to Listing Rule 4.7B

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
	-	-

7.5 **Unused financing facilities available at quarter end**

-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	<362>
8.2 Cash and cash equivalents at quarter end (Item 4.6)	837
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	837
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	2.3

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 January 2020

Authorised by: By the Audit Committee
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.